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Contribution of Lung Fibroblast
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ABSTRACT
Background: The fibrotic process in airway remodeling of asthma may be characterized by an exaggerated
deposition of extracellular matrix (ECM) components such as fibronectin and type I, III and IV collagen. In the
present study, we established airway remodeling model mice and examined the mechanism of fibrotic change
by measuring chemotactic activity of lung fibroblasts and quantifying collagen content in lung tissues.
Methods: Airway remodeling model mice were made by ovalbumin (OA) sensitization and inhalation. Bron-
choalveolar lavage (BAL) and bronchial biopsy were performed. Cell migration was assessed by the Boyden’s
chamber technique. The collagen content of lung tissue was measured using ELISA.
Results: The chemotactic activity in lung fibroblasts toward the mouse BAL fluid (BALF) was significantly in-
creased in OA-inhaled mice. Total soluble collagen content was significantly increased in OA-inhaled mice. We
observed markedly increased collagen deposition around the airway wall in OA-inhaled mice, which was not
shown in saline-inhaled mice. Furthermore, fibronectin in the BALF of OA-inhaled mice was significantly higher
than that in the control mice.
Conclusions: The total soluble collagen content increased during the fibrotic change of airway remodeling in
asthma. Furthermore, migration of fibroblasts may play a key role in this remodeling process, and fibronectin
and type I and IV collagen seem to be chemotactic factors for the fibroblasts.
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INTRODUCTION
Airway remodeling in asthma is recognized as irre-
versible structural changes.1 However, several recent
reports have revealed that remodeling might be the
process of repair from injury. CysLT1 receptor block-
ade has anti-airway remodeling effects including fi-
brotic change in animal models.2-4 In addition, Ohta et
al. demonstrated that the presence of fibrotic change
declined and returned to a normal level of airway
thickening following treatment with a neutralizing
anti-TGF-β antibody.5 Another report noted that treat-
ment with anti-platelet-derived growth factor (PDGF)
antibody significantly decreased the hydroxyproline
content in mice sensitized with silica particles.6
The fibrotic process of airway remodeling in
asthma may be caused by an exaggerated induction
and deposition of extracellular matrix (ECM) such as
fibronectin or type I, III or IV collagen. Part of these
structural changes may be induced by migration of fi-
broblasts activated by fibronectin secreted by bron-
chial epithelial cells and fibroblasts.7,8
In the present study, we established airway remod-
eling model mice and evaluated the mechanism of fi-
brotic change by measuring the chemotactic activity
of lung fibroblasts and quantifying the collagen con-
tent of lung tissue.
METHODS
ANIMALS
Seven-week-old female BALBc mice were purchased
from CLEA Japan, Inc. (Tokyo, Japan). Experiments
were undertaken following the guidelines for the care
and use of experimental animals of the Japanese As-
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sociation for Laboratory Animal Science, published in
1987.
PREPARATION OF AIRWAY REMODELING
MODEL
Airway remodeling model mice were made by sensi-
tizing mice with ovalbumin (OA; Sigma, St. Louis,
MO, USA) according to the method of Tanaka and
coworkers.9 Briefly, mice were actively sensitized by
intraperitoneal injections of 50 μg OA with 1 mg alum
on days 0 and 12. Starting on day 22, they were ex-
posed to OA (1% diluted in sterile physiological sa-
line) for 30 minutes every day for 4 consecutive
weeks. Control mice were sensitized and exposed to
saline in a similar manner. Bronchoalveolar lavage
(BAL) and bronchial biopsy were performed 24 hours
after the final inhalation.
SAMPLING OF BAL FLUID
Mice were sacrificed on day 26, 29, 36, 43 or 50 with
an intraperitoneal injection of pentobarbital sodium
salt (Nacalai Tesque, Inc., Kyoto, Japan). The lungs
were washed 4 times with 0.5 ml phosphate-buffered
saline (PBS) containing 0.1% bovine serum albumin
(BSA; Sigma) and 0.05 mM EDTA-2Na (Sigma). This
procedure was repeated three times. BAL fluid
(BALF) was centrifuged at 1500 × g for 5 minutes.
Each supernatant was recovered and stored at −30℃.
PREPARATION OF LUNG FIBROBLASTS
Normal human lung fibroblasts (NHLF) were pur-
chased from Clonetics (Cambrex Bio Science Walk-
ersville, Inc. Walkersville, MD, USA). The cells were
cultured on tissue culture dishes (Falcon; Becton-
Dickinson Labware, Franklin Lakes, NJ, USA) with
FGM-2 media (Clonetics). Cells were incubated at
37℃, 5% CO2.
CELL MIGRATION ASSAYS
Cell migration was measured by the Boyden’s blind-
well chamber technique10 using 48-well multiwell
chambers (Neuroprobe, Inc., Bethesda, MD, USA).
An 8-μm pore size membrane (Nuclepore, Pleasan-
ton, CA, USA) was used. The mouse BALF, or an
ECM component such as fibronectin or type I, III or
IV collagen, was placed into each of the bottom wells.
Cells, trypsinized and resuspended at 1 × 106 cells
ml, were placed into each of the top wells. The cham-
ber was then incubated at 37℃, 5% CO2 for 6 hours.
After incubation, cells that had not migrated were
scraped off the upper surface of the membrane, and
the membrane was air-dried. Cells were stained with
Diff-QuickⓇ (International Reagent Corp., Kobe, Ja-
pan). Cell migratory activity is shown as the total
number of migrated cells counted in ten high-power
fields using a light microscope (Olympus, Tokyo, Ja-
pan) with × 400 magnification.
FIBRONECTIN ELISA
Fibronectin in BALF was measured using sandwich
ELISA.11 MicrotestTM 96-well ELISA plates (BD Bi-
osciences, Bedford, MA, USA) were coated with rab-
bit anti-fibronectin polyclonal antibody (10 μgml;
Dako, Glostrup, Denmark) in a coating buffer (0.01
M phosphate buffer, 0.15 M NaCl, pH 7.2) overnight
at 4℃. Each plate was blocked with 2% BSA-PBS for 2
hours at room temperature. Then samples were
added to each plate and incubated for 2 hours at
room temperature. Polyclonal rabbit anti-fibronectin
antibody conjugated with peroxidase (0.22 μgml;
Dako) was added overnight at 4℃. Chromogen sub-
strate containing 3, 3’, 5, 5’-tetramethyl-benzidine
(Dako) was added, and optical readings at 492 nm
were obtained using an ELISA plate reader (Wako,
Osaka, Japan). Mouse fibronectin (Innovative Re-
search, Inc., Southfield, MI, USA) was used to obtain
the standard curves for calculation of fibronectin con-
centration in BALF. The detection limit of this ELISA
was 40 ngml.
COLLAGEN ASSAYS
Lung collagen content was determined by measuring
soluble collagen using the Sircol Collagen Assay kit
(Biocolor Ltd., Newtownabbey, Northern Ireland) ac-
cording to the manufacturer’s instructions. Briefly,
lungs were extracted with 0.5 M acetic acid contain-
ing 1 mg pepsin (Sigma) per 10 mg lung tissues.
Each sample was incubated overnight at room tem-
perature with stirring. After centrifugation, 100 μl of
each supernatant was mixed for 30 minutes at room
temperature with 1 ml of Sircol dye reagents. After
centrifugation, each collagen-dye pellet was resus-
pended in 1 ml of Alkali reagent and optical density
was measured at 540 nm using an ELISA plate
reader.
HISTOLOGICAL EXAMINATION
Bronchial biopsy was performed 24 hours after the fi-
nal antigen challenge. The lungs were distended by
injection of 10% buffered formalin via the trachea, ex-
cised and immersed in the same fixative for 24 hours.
Tissues were sliced and embedded in paraffin, and 2―
3 μm sections were stained with Elastica van Gieson
or Masson-trichrome.
STATISTICAL ANALYSIS
Data were expressed as means ± SEM. Statistical sig-
nificance between saline-inhaled and OA-inhaled
mice was estimated using the two-tailed Student’s t
test. Probability values of less than 0.05 were consid-
ered to indicate significant differences.
RESULTS
MIGRATION OF NHLF TOWARD BALF
To determine whether the migration of lung fibro-
blasts contributed to the fibrotic process of airway re-
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Fig. 1 Migration of NHLF toward BALF. Values represent 
the means ± SEM in triplicate. ＊p＜0.05, ＊＊p＜0.01 (vs 
saline-inhaled mice).
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Fig. 2 Migration of NHLF toward ECM components. Fi
bronectin and type I, II and IV colagen were used as 
chemoatractants. Values represent the means ± SEM in 
triplicate.
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Fig. 3 The concentration of fibronectin in BALF. Values 
represent the means ± SEM of 4 mice. ＊ p＜ 0.01 (vs 
saline-inhaled mice).
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Fig. 4 Total soluble colagen content in lung tissue of mice. 
Values represent the means ± SEM of 3―4 mice. ＊ p＜
0.05, ＊＊p＜0.01 (vs saline-inhaled mice).
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modeling, we evaluated the chemotactic activity in
the NHLF toward the mouse BALF. The chemotactic
activity increased significantly in OA-inhaled mice
compared with saline-inhaled mice (Fig. 1). The num-
ber of migrated cells declined gradually in both
groups.
MIGRATION OF NHLF TOWARD EXTRACELLU-
LAR MATRIX COMPONENTS
As we considered ECM components in the mouse
BALF to be chemotactic factors for NHLF, we exam-
ined whether there was chemotactic activity in NHLF
toward fibronectin or type I, III or IV collagen (Fig.
2). Among the four ECM components, fibronectin
and type I and IV collagen showed a dose-dependent
increase in chemotactic activity, whereas type III col-
lagen showed little chemotactic activity.
MEASUREMENT OF MOUSE FIBRONECTIN
We measured fibronectin by sandwich ELISA (Fig.
3). The results demonstrated that BALF of OA-
inhaled mice contained a significantly higher concen-
tration of fibronectin than did that of saline-inhaled
mice. In addition, fibronectin in the BALF of OA-
inhaled mice increased gradually and peaked at day
29, and then declined. In contrast, the fibronectin in
the BALF of control mice showed relatively little
change throughout the period of OA inhalation.
TOTAL SOLUBLE COLLAGEN CONTENT IN
LUNG TISSUE
We measured the total soluble collagen content in
lung tissues using the ELISA. Total soluble collagen
content increased in OA-inhaled mice, whereas the
total soluble collagen content in saline-inhaled mice
changed little (Fig. 4).
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Fig. 5 Elastica van Gieson staining of lung sections from OA-inhaled mice (A) and saline-inhaled mice 
(B) on day 50. Original magnifications×200.
A B
Fig. 6 Masson-trichrome staining of lung sections from OA-inhaled mice (A) and saline-inhaled mice (B) 
on day 29. Original magnifications×200.
A B
HISTOLOGICAL ANALYSIS
We evaluated the structural changes in lung tissue.
OA-inhaled mice at day 50 (4-week exposure) showed
a markedly increased deposition of collagen around
the airway wall compared with that of saline−inhaled
mice (Fig. 5A vs Fig. 5B). Masson-trichrome staining
of lung tissue at day 29 demonstrated highly in-
creased collagen in OA-inhaled mice (Fig. 6A), which
was not observed in the airway wall of saline-inhaled
mice (Fig. 6B). Furthermore, in OA-inhaled mice,
abundant inflammatory cell infiltration and goblet cell
hyperplasia were detected.
DISCUSSION
In the present study, we demonstrated that the che-
motactic activity for fibroblasts was significantly in-
creased in the BALF of repeated antigen-inhaled
mice. Furthermore, we confirmed that fibronectin
and type I and IV collagen had chemotactic activity
for fibroblasts. Furthermore, we found that the con-
centration of fibronectin in the BALF of repeated
antigen-inhaled mice increased significantly. It has
been reported that fibronectin is included in bron-
chial epithelial cell or fibroblast conditioned medium
and chemotactic factors for fibroblasts in vitro.7,8 Our
current study suggests that not only fibronectin but
also type I and IV collagen had chemotactic activity
for fibroblasts, and they were included in the BALF of
repeated antigen-inhaled mice in vivo. Moreover, the
number of migrated cells over time gradually de-
clined, which suggests that chemotactic factors in the
BALF decreased. That is, ECM-involved fibrotic
change will occur during the early stage after the in-
jury of epithelial cells and then stimulate the migra-
tion of fibroblasts.
Many reports have demonstrated that cell migra-
tion occurs beyond the difference between species.
Rat lung fibroblasts (RLF) and Swiss mouse 3T3 cells
showed chemotactic activity toward human PDGF.12
Human airway epithelial cells and fibroblasts may re-
lease a chemotactic activity for rat basophilic leuke-
mia cells (RBL-2H3) and normal rat peritoneal mast
cells (RPMC).13,14 Moreover, it has been reported
that human lung fibroblasts migrate significantly for
Role of Fibroblast Migration
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bovine bronchial epithelial cell conditioned medium.7
Therefore, we conclude that cell migration occurs be-
tween different species.
In the airway of asthma patients, the number of my-
ofibroblasts and subepithelial collagen thickness
were correlated.15,16 Another report demonstrated
that myofibroblasts produce ECM more than fibro-
blasts.17 Differentiation of myofibroblasts from fibro-
blasts was induced by TGF-β,18 and it was reported
that chemotactic activity for fibroblasts was increased
by the action of TGF-β.19 Furthermore, fibronectin in-
creased in the BALF of asthma patients, and the
change was positively correlated with the level of
TGF-β.20 These findings suggest that not only fi-
bronectin but also TGF-β play an important role in
the fibrotic process.
In our experiment, we assayed total soluble colla-
gen content in lung tissues. Although many reports
using hydroxyproline content as an indicator of fi-
brotic change have been published,9,11,21 we believe
that our current results are in agreement with the re-
sults in those reports.
As P. K. Jeffery suggested, the term “fibrosis” was
an unfortunate application as a view of airway remod-
eling in asthma.22 Fibrosis as reticulin indicates that
collagen fibers lie relatively deeper in the interstitium
of the airway wall. However, collagen fibers increased
in the lung tissue in repeated antigen-inhaled mice as
shown in our results. Thus, a similar change as fibro-
sis may occur in airway remodeling processes in
asthma.
In previous reports, remodeling has been consid-
ered to consist of irreversible structural changes,
since dexamethasone treatment had limited ef-
fect.23,24 However, several studies have demonstrated
that CysLT1 receptor blockade, anti-TGF-β antibody
and anti-PDGF antibody have anti-airway remodeling
effects including fibrotic change in animal models.2-6
Moreover, Saetta et al. reported that the avoidance of
exposure to toluene diisocyanate (TDI) was associ-
ated with suppressing the thickness of fibrotic
change and the number of fibroblasts in occupational
asthma.25 These results suggest that airway remodel-
ing might have repair processes and reversible
change.
In summary, we confirmed that total soluble colla-
gen content increased in the fibrotic change in airway
remodeling processes in asthma. Moreover, the mi-
gration of fibroblasts may play a key role in this proc-
ess. Thus, understanding the mechanisms of the fi-
brotic process in airway remodeling is important for
asthma therapy.
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